Garadacimab - CISMeF

Preferred Label : Garadacimab;

NCIt definition : A humanized monoclonal antibody against the activated coagulation factor XIIa (FXIIa), with potential anti-inflammatory and anticoagulant activities. Upon administration, garadacimab targets and binds to FXIIa, blocking the activation of both the kallikrein-kinin system and the intrinsic pathway of coagulation. Blocking the activation of the kallikrein-kinin system may reduce inflammation as well as the production of bradykinin (BK). This may prevent BK-driven edema in hereditary angioedema (HAE). Blocking the activation of the intrinsic pathway of coagulation may lead to anti-coagulation. This may also prevent or improve pulmonary edema not associated with HAE and improve the associated decrease in blood oxygen levels.;

UNII : 32W6AJL0DY;

CAS number : 2162134-62-3;

Molecule name : CSL 312; CSL-312;

NCI Metathesaurus CUI : CL971884;

Détails

Origin ID

C166633;

UMLS CUI

C5238067;

Currated CISMeF NLP mapping
- Garadacimab [SMS substance]
Manual BTNT mappings - CISMeF
- garadacimab [ATC Code]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients